CFO Ignelzi bought 10.0K shares in 2 purchases for $100,988.00 as RAPP down 65.7% from 52-week high
Ignelzi, the Chief Financial Officer of Rapport Therapeutics, made 2 separate purchases totaling 10,000 shares for $100,988.00, bringing his post-transaction holdings from zero to 10,000 shares. The purchases occurred at $10.10 and $9.98 per share on consecutive trading days (March 12-13, 2025), during a period when the stock has declined 65.7% from its 52-week high of $29.23 and 36.3% over the prior 30 days. The company reported a net loss of $17,537,000.00 for its most recent full fiscal year, establishing an unprofitable operating backdrop. An incoming CFO's initial equity purchase—particularly at this scale and timing relative to sharp recent declines—merits scrutiny regarding both his assessment of intrinsic value and any information asymmetries he may possess.